Page 43 - Rna News Today

Germany's BioNTech, a company famed for its COVID-19 vaccine, announced Friday that it signed a memorandum to establish a strategic partnership with the UK for mRNA cancer therapies, according to Anadolu Agency. The partnership aims to provide personalized mRNA cancer therapies for up to 10,000 patients by the end of 2030

Read more about Health News Roundup: UK PM Sunak to meet health service leaders as crisis drags on; China in talks with Pfizer for generic COVID drug - sources and more on Devdiscourse

Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UKBioNTech aims to design and roll out randomized

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studiesAll candidates use CureVac's advanced second-generation mRNA backbone

Oncologists warn of explosive cancer relapses in patients who were in stable remission before receiving their COVID boosters.

Germany's BioNTech, a company famed for its COVID-19 vaccine, announced Friday that it signed a memorandum to establish a strategic partnership with the UK for mRNA cancer therapies, according to Anadolu Agency. The partnership aims to provide personalized mRNA cancer therapies for up to 10,000 patients by the end of 2030

"The insulting and indecent act of a French publication in publishing cartoons against the religious and political authority will not go without an effective and decisive response," tweeted Iran's Foreign Minister Hossein Amir-Abdollahian.

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditionsCytomX to receive $35 million upfront payment

A small study shows promise in deploying mRNA technology against melanoma — but fighting tumors is vastly more complex than tackling COVID-19.

Initiating a strategic collaboration